🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Catherine Wood’s DRTS Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+292,134 Shares
Current Position
292,134 Shares
$2.07 M Value

Catherine Wood's DRTS Position Overview

Catherine Wood (via Ark Investment Management LLC) currently holds 292,134 shares of Alpha Tau Medical Ltd. (DRTS) worth $2.07 M, representing 0.02% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Catherine Wood has initiated a new position in DRTS, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Catherine Wood's Alpha Tau Medical (DRTS) Holding Value Over Time

Track share changes against reported price movement

Quarterly Alpha Tau Medical (DRTS) Trades by Catherine Wood

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +292,134 New Buy 292,134 $7.07

Catherine Wood's Alpha Tau Medical Investment FAQs

Catherine Wood first purchased Alpha Tau Medical Ltd. (DRTS) in Q1 2026, acquiring 292,134 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Catherine Wood has held Alpha Tau Medical Ltd. (DRTS) for 1 quarters since Q1 2026.

Catherine Wood's largest addition to Alpha Tau Medical Ltd. (DRTS) was in Q1 2026, adding 292,134 shares worth $2.07 M.

According to the latest 13F filing for Q1 2026, Catherine Wood's firm, Ark Investment Management LLC, owns 292,134 shares of Alpha Tau Medical Ltd. (DRTS), valued at approximately $2.07 M.

As of the Q1 2026 filing, Alpha Tau Medical Ltd. (DRTS) represents approximately 0.02% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.

Catherine Wood's peak holding in Alpha Tau Medical Ltd. (DRTS) was 292,134 shares, as reported at the end of Q1 2026.